先宗树, 李光辉, 盖军伟, 朱敏, 马琳琳, 鞠佃文, 万亚坤. 内吞型EpCAM纳米抗体的筛选及鉴定J. 药学学报, 2020,55(10): 2405-2413. doi: 10.16438/j.0513-4870.2020-1359
引用本文: 先宗树, 李光辉, 盖军伟, 朱敏, 马琳琳, 鞠佃文, 万亚坤. 内吞型EpCAM纳米抗体的筛选及鉴定J. 药学学报, 2020,55(10): 2405-2413. doi: 10.16438/j.0513-4870.2020-1359
XIAN Zong-shu, LI Guang-hui, GAI Jun-wei, ZHU Min, MA Lin-lin, JU Dian-wen, WAN Ya-kun. The screening and identification of internalized nanobody against EpCAM J. Acta Pharmaceutica Sinica, 2020,55(10): 2405-2413. doi: 10.16438/j.0513-4870.2020-1359
Citation: XIAN Zong-shu, LI Guang-hui, GAI Jun-wei, ZHU Min, MA Lin-lin, JU Dian-wen, WAN Ya-kun. The screening and identification of internalized nanobody against EpCAM J. Acta Pharmaceutica Sinica, 2020,55(10): 2405-2413. doi: 10.16438/j.0513-4870.2020-1359

内吞型EpCAM纳米抗体的筛选及鉴定

The screening and identification of internalized nanobody against EpCAM

  • 摘要: 上皮细胞黏附分子(epithelial cell adhesion molecule,EpCAM)是肿瘤靶向治疗的热门靶点,本研究开发了3株高特异性针对EpCAM的胞吞型纳米抗体,为基于此靶点的免疫毒素研究提供基础。研究前期对骆驼免疫EpCAM-Fc蛋白,构建了高质量的噬菌体展示纳米抗体文库,运用噬菌体展示技术通过3轮淘选成功获得了17株互补决定区(complementarity determining region,CDR)3序列不同的EpCAM纳米抗体,原核纯化获得高纯度的抗体蛋白后,流式细胞术确定其中7株具有细胞水平高结合活性。动物实验经复旦大学药学院实验动物伦理委员会(IACUC)批准。通过流式细胞术和激光共聚焦显微术最终鉴定出3株具有较高胞吞活性的EpCAM纳米抗体,且ForteBio测定具高亲和力。本研究以期为EpCAM阳性肿瘤的靶向治疗开辟新的途径,并为其他靶点的纳米抗体免疫毒素研究提供指导。

     

    Abstract: Epithelial cell adhesion molecule (EpCAM) is a popular target for cancer therapy. In this research, 3 nanobodies with high specificity and endocytosis activity against EpCAM were developed, which provides a basis for the study of immunotoxin based on EpCAM. In our preliminary experiments, we have immunized a camel with EpCAM-Fc antigen and constructed a high-quality phage display library. Seventeen nanobodies with different complementarity determining region (CDR) 3 sequences have been screened after 3 rounds of biopanning by phage display technology. The animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Fudan University School of Pharmacy. After purification, 7 nanobodies showed high cell binding activity by fluorescent activated cell sorting (FACS) identification. Furthermore, 3 nanobodies presented high endocytosis activity based on FACS and laser confocal microscopy, which also showed high affinity to EpCAM measured by ForteBio. According to this study, we aimed to provide a novel alternative approach to the EpCAM-targeted therapy and to provide guidance for the study of nanobody based immunotoxins for other targets.

     

/

返回文章
返回